Madrigal Pharmaceuticals stock gets fresh Rezdiffra data

Published on 10/07/2026 at 06:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal Pharmaceuticals stock closed at USD 496.45 on October 6, 2026, after new Rezdiffra data covered 738 patients. Q2 revenue rose 71.2 percent to USD 364.25 million.

MDGL, US5588681057, Illustration mit AI erstellt.

Madrigal Pharmaceuticals stock (ISIN US5588681057) closed at USD 496.45 on Nasdaq on October 6, 2026, after the company published new Rezdiffra data covering 738 patients. The analysis adds clinical support for resmetirom across common genetic risk groups in MASH.

Rezdiffra data broaden the case

According to Madrigal Pharmaceuticals on October 6, 2026, a prespecified secondary analysis from the Phase 3 MAESTRO-NASH trial found consistent Rezdiffra effects across PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7 risk groups.

The strongest numerical difference appeared in the PNPLA3 groups. MASH resolution reached 38.4 percent, 30.8 percent and 30.5 percent among treated patients across low, intermediate and high-risk groups, versus 12.9 percent, 5.1 percent and 11.7 percent for placebo.

The same analysis covered baseline and Week 52 liver biopsies, but Madrigal said the secondary study was not prospectively powered to detect small genotype-treatment interactions. Limited numbers in certain groups leave smaller variant-specific effects open for further study.

Revenue growth meets a loss

The commercial picture was already accelerating before the publication. MarketBeat reported that Q2 2026 revenue reached USD 364.25 million, up 71.2 percent from the prior-year quarter, while adjusted EPS was a loss of USD 1.99 against a consensus loss of USD 2.68.

The USD 0.69 adjusted EPS beat and the USD 12.12 million revenue lead over the USD 352.13 million estimate show why Rezdiffra uptake remains central to the valuation. Revenue growth is substantial, but the quarterly loss keeps profitability and commercialization costs in the foreground.

Analysts keep targets above price

According to StockUpside on October 5, 2026, 18 analysts carried a Buy consensus, with a USD 682.11 average target, a USD 962.00 high and a USD 543.00 low. The consensus target stood 36.6 percent above the USD 499.40 price shown by the service.

That spread gives the October 6 clinical publication a clear investor test: broader treatment response can support commercial reach, while the company still has to convert revenue growth into sustainable earnings.

MDGL stays below its yearly high

MDGL's October 6 close of USD 496.45 was USD 2.83, or 0.57 percent, above the prior close. The stock's USD 393.61 to USD 615.00 52-week range places the close 19.3 percent below the yearly high, while market capitalization stood at USD 11.4 billion and volume reached 330,280 shares.